Mizuho Maintains Buy on ResMed, Raises Price Target to $195
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone has reaffirmed a Buy rating on ResMed (NYSE:RMD) and increased the price target from $180 to $195.
January 26, 2024 | 7:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone maintains a Buy rating on ResMed and raises the price target from $180 to $195, indicating a positive outlook on the stock.
The increase in price target by Mizuho reflects a positive assessment of ResMed's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100